Avalo Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Avalo Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Avalo Therapeutics Inc
Rating: 2.11341675
Author: Trendlyne DVM scores

about

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

4.80 -0.10 (-2.04%)

70.00% Fall from 52W High

32,067

XNAS Volume

XNAS 15 Jul, 2025 5:30 PM (EDT)

Not Eligible

Mid Valuation

49.7 / 100

Technically Bearish

34.9 / 100

1Yr Price target upside is 543%

7 analysts

Avalo Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Avalo Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

70.00% Fall from 52W High

SWOT Analysis

Avalo Therapeutics Inc Live Price Chart